And some clinical studies have even demonstrated the efficacy and safety of a three-drug regimen of CDK4/6i combined with endocrine therapy and anti-Her2 in HER2+ BC, an interesting chemotherapy-free combination. The gene discussed is ERBB2; the disease is breast cancer.